RECURRENT BLADDER UROTHELIAL CARCINOMA
Clinical trials for RECURRENT BLADDER UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT BLADDER UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT BLADDER UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to fight tough bladder cancer
Disease control OngoingThis study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced or spreading bladder cancer who cannot take standard cisplatin chemo. About 72 adults with recurrent or metastatic urothe…
Matched conditions: RECURRENT BLADDER UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 18, 2026 11:51 UTC
-
New drug combo targets tough bladder cancers
Disease control OngoingThis early-phase trial tests a combination of two drugs (erdafitinib and enfortumab vedotin) in about 24 people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. The goal is to find the safest dose and see if the combo can shrink or stabilize the…
Matched conditions: RECURRENT BLADDER UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 17, 2026 12:04 UTC
-
Can a simple test predict who will respond to immunotherapy?
Knowledge-focused OngoingThis study looks at whether certain gene mutations (ARID1A and KDM6A) and a protein called CXCL13 in tumors can help predict if the immunotherapy drug nivolumab will work for people with advanced bladder cancer that has spread. Only 6 participants with these specific gene changes…
Matched conditions: RECURRENT BLADDER UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 17, 2026 12:08 UTC